<DOC>
	<DOC>NCT01687920</DOC>
	<brief_summary>This study should estimate the dose proportionality of BAY94-8862 IR tablets.</brief_summary>
	<brief_title>Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Healthy male subject Age: 18 to 46 years (inclusive) at the first screening examination Ethnicity: White Body mass index (BMI): &gt;= 18 and &lt;= 29.9 kg / mÂ² Clinically relevant findings in the ECG (electrocardiogram) such as a second or thirddegree AV block, prolongation of the QRS complex over 120 msec Systolic blood pressure below 100 or above 140 mmHg Diastolic blood pressure below 50 or above 90 mmHg Heart rate below 50 or above 95 beats/ min Positive results for hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibodies (antiHCV), human immune deficiency virus antibodies (antiHIV 1+2) Participation in another clinical study during the preceding 3 months (Last Treatment from previous study to First Treatment of new study)</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>46 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Cardiac disorders</keyword>
</DOC>